Locatelli F, et al. - Cardiovascular outcomes and all-cause mortality associated with monthly methoxy polyethylene glycol-epoetin beta were compared with those of the shorter-acting agents, epoetin alfa/beta and darbepoetin alfa, in patients with anemia of CKD via performing a multicenter, open-label, noninferiority trial. In this trial, researchers randomized 2,818 patients to receive methoxy polyethylene glycol-epoetin beta or reference erythropoiesis-stimulating agents, stratified by maintenance or correction treatment status and C-reactive protein level. Outcomes support the non-inferiority of once-monthly methoxy polyethylene glycol-epoetin beta to conventional, shorter-acting erythropoiesis-stimulating agents with respect to rates of major adverse cardiovascular events or all-cause mortality.